Virtual Screening Strategy Combined Bayesian Classification Model, Molecular Docking for Acetyl-CoA Carboxylases Inhibitors

Abstract

Introduction: Acetyl-CoA Carboxylases (ACC) have been an important target for the therapy of metabolic syndrome, such as obesity, hepatic steatosis, insulin resistance, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), and some other diseases. Methods: In this study, virtual screening strategy combined with Bayesian categorization modeling, molecular docking and binding site analysis with protein ligand interaction fingerprint (PLIF) was adopted to validate some potent ACC inhibitors. First, the best Bayesian model with an excellent value of Area Under Curve (AUC) value (training set AUC: 0.972, test set AUC: 0.955) was used to screen compounds of validation library. Then the compounds screened by best Bayesian model were further screened by molecule docking again. Results: Finally, the hit compounds evaluated with four percentages (1%, 2%, 5%, 10%) were verified to reveal enrichment rates for the compounds. The combination of the ligandbased Bayesian model and structure-based virtual screening resulted in the identification of top four compounds which exhibited excellent IC 50 values against ACC in top 1% of the validation library. Conclusion: In summary, the whole strategy is of high efficiency, and would be helpful for the discovery of ACC inhibitors and some other target inhibitors.</P>

Machine‐Learning‐Assisted Nanozyme Design: Lessons from Materials and Engineered Enzymes

“…The method of computing conditional probabilities is called Bayesian classification, [ 25 ] and this is a general term for a class of classification algorithms based on Bayes theorem. Bayesian algorithms make assumptions of independence for conditional probability distributions, leading to improved learning efficiency and classification results.…”

Virtual Screening Algorithms in Drug Discovery: A Review Focused on Machine and Deep Learning Methods

“…In repositioning and drug discovery scenarios, the Bayesian algorithms identify the probability of a compound possessing biological activity for a specific target. Therefore, Bayesian techniques can be used, for instance, to find novel active scaffolds against the same target or to find compounds that are more active or that possess improved ADMET properties when compared to the main structure [86]. However, Bayesian networks were not explicitly superior to much simpler approaches, based, for example, on the Tanimoto coefficient [87].…”

Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation

“…Currently, the therapeutic concepts for NASH consist of reducing hepatic fat accumulation, relieving oxidative stress and inflammation, and delaying and reversing fibrosis . Many efforts have been made on drug design and discovery to provide solutions. − Some compounds have entered phase III trials, including obeticholic acid (farnesoid X receptor agonist), VK-2809 (thyroid hormone receptor β agonist), GFT-505 (peroxisome proliferator-activated receptor α/δ agonist), cenicriviroc (C–C chemokine receptor type 2/5 antagonist), and GS-4997 (apoptosis signal-regulating kinase 1 inhibitor). , However, none of them has been approved for marketing. Hence, anti-NASH drugs are in urgent clinical needs.…”